Table 3.

Input variables and distribution for Monte Carlo simulation sensitivity analyses

Input variable	Voriconazole	LAmB
Fever without baseline infection	Triangular distribution, 92.03%-96.87%-100%	Triangular distribution, 93.65%-98.58%-100%
Therapeutic success	Triangular distribution, 24.10%-25.37%-26.64%	Triangular distribution, 28.55%-30.05%-31.55%
Therapeutic failure	Triangular distribution, 70.90%-74.63%-78.36%	Triangular distribution, 66.45%-69.95%-73.45%
Death	Triangular distribution, 10.45%-11.00%-11.55%	Triangular distribution, 8.16%-8.59%-9.02%
Breakthrough infection	Triangular distribution, 2.40%-2.67%-2.94%	Triangular distribution, 6.50%-7.22%-7.94%
Premature discontinuation	Triangular distribution, 12.30%-13.67%-15.04%	Triangular distribution, 8.66%-9.62%-10.58%
Persistent fever	Triangular distribution, 65.40%-72.67%-79.94%	Triangular distribution, 67.11%-74.57%-82.03%
Fever with baseline infection	Triangular distribution, 2.97%-3.13%-3.29%	Triangular distribution, 1.20%-1.42%-1.49%
Therapeutic success	Triangular distribution, 43.84%-46.15%-48.46%	Triangular distribution, 63.34%-66.67%-70.00%
Therapeutic failure	Triangular distribution, 51.16%-53.85%-56.54%	Triangular distribution, 31.66%-33.33%-35.00%
Ward “per diem”	Discrete, 30% at TL193.40 and 70% at TL30.00
ICU length of stay	Log-normal, mean 5 days, standard deviation 2.5 days
Overall treatment duration	Log-normal, mean 10 days, standard deviation 2 days
Proportion of oral voriconazole use	Triangular distribution, 0-22-50%